Citigroup
IMPL

Citigroup’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Citigroup’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-64
Closed -$240 – 5969
2022
Q4 		$240 Sell
64
-281
-81% -$1.02K ﹤0.01% 5582
2022
Q3 		$2K Sell
345
-60
-15% -$459 ﹤0.01% 5567
2022
Q2 		$4K Sell
405
-331
-45% -$2.42K ﹤0.01% 5734
2022
Q1 		$5K Sell
736
-1,321
-64% -$9.98K ﹤0.01% 5857
2021
Q4 		$18K Buy
2,057
+1,433
+230% +$14.3K ﹤0.01% 5423
2021
Q3 		$8K Buy
624
+369
+145% +$5.36K ﹤0.01% 5532
2021
Q2 		$2K Buy
+255
New +$3.04K ﹤0.01% 6002

Other funds holding IMPL

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $375M AUM 72.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Citigroup's IMPL Position: Q1 2023 in Review

Citigroup sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q1 2023, closing a stake of 64 shares — an estimated $240 sold.

Citigroup first reported a position in IMPL in Q2 2021 and held it in 7 quarters. The position peaked at $18K in Q4 2021. 32 funds tracked by Wall St. Rank hold IMPL as of Q1 2023.

  • Citigroup reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Citigroup sold 64 Impel Pharmaceuticals Inc. Common Stock shares in Q1 2023, an estimated $240.
  • Citigroup first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q2 2021 and held it in 7 quarters.
  • Citigroup's Impel Pharmaceuticals Inc. Common Stock position peaked at $18K in Q4 2021.
  • 32 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q1 2023.

Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.